Drugs / TAS-109
TAS-109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00824161 | Jan → Nov 2009 | colorectal cancer | Taiho Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00824161 ↗ |
| Known as | Cndac | ChEMBL registry synonym — accepted as the source's own label CHEMBL337450 ↗ |
| Known as | Deoxycytidine analogue tas-109 | ChEMBL registry synonym — accepted as the source's own label CHEMBL337450 ↗ |
| Known as | Radgocitabine | ChEMBL registry synonym — accepted as the source's own label CHEMBL337450 ↗ |
| Modality | Small molecule | — CHEMBL337450 ↗ |
| Route | Intravenous | “continuous central intravenous infusion” NCT00824161 ↗ |